Pfizer recalls sickle cell anaemia drug due to risk of complications and death
US drugmaker Pfizer said on Wednesday it was recalling Oxbryta, a treatment for sickle-cell anaemia, from all markets where it is approved, citing risks of painful complications and fatalities. Pfizer acquired Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022.
POPULAR POSTS
Israel rejects Lebanon ceasefire plan
September 27, 2024
Heavy rains paralysed traffic, closed schools in Mumbai and nearby regions
September 27, 2024
Tropical Storm John will become a hurricane again
September 27, 2024
Hurricane Helen is moving towards Florida with strong winds and storm waves
September 27, 2024
LIVE STREAM